财务数据和关键指标变化 - 第四季度全球LCI销售额同比下降1.8%,但排除PPE产品和COVID-19检测试剂盒后,LCI销售额增长5% [30] - 第四季度GAAP营业利润率为2.15%,同比下降387个基点;非GAAP营业利润率为6.74%,同比提高56个基点 [31] - 第四季度GAAP有效税率23.6%,非GAAP有效税率22.2% [32] - 第四季度GAAP净利润4700万美元,每股收益0.34美元;非GAAP净利润1.65亿美元,每股收益1.21美元 [32] - 第四季度摊销费用3070万美元,每股收益0.14美元 [33] - 第四季度运营现金流2.54亿美元,同比下降8.3% [38] - 2023年非GAAP每股收益预期为5.25 - 5.42美元,同比下降2% - 1% [42] 各条业务线数据和关键指标变化 - 第四季度全球牙科销售额20亿美元,LCI销售额同比下降2.6%;排除PPE产品后,LCI销售额增长0.9% [35] - 第四季度北美牙科LCI销售额同比下降3.4%,但排除PPE产品后,LCI销售额增长1.3% [35] - 第四季度国际牙科LCI销售额同比下降1.4%,排除PPE产品后,LCI销售额增长0.7% [35] - 第四季度牙科专业产品销售额约2.47亿美元,LCI销售额同比增长0.3% [35] - 第四季度全球医疗销售额12亿美元,LCI销售额同比下降1.3%;排除PPE产品和COVID-19检测试剂盒后,LCI销售额增长14.9% [37] - 第四季度全球技术和增值服务销售额1.87亿美元,LCI销售额同比增长3.4% [36] 各个市场数据和关键指标变化 - 第四季度北美牙科消费品LCI销售额同比下降5.1%,但排除PPE产品后,LCI销售额增长1.3% [35] - 第四季度国际牙科消费品LCI销售额同比下降1.7%,排除PPE产品后,LCI销售额增长0.7% [35] - 第四季度北美牙科设备LCI销售额同比增长1.3% [35] - 第四季度国际牙科设备LCI销售额同比下降0.4% [35] - 第四季度医疗设备和药品销售额强劲增长 [26] 公司战略和发展方向和行业竞争 - 推进2022-2024年BOLD+1战略计划,重点关注数字化转型、全球电子商务平台、人工智能应用等 [9][10][11] - 通过收购Midway Dental、Condor Dental、Unitas和Biotech Dental等公司,扩大市场覆盖和产品组合 [12] - 实施重组计划,优化全球房地产布局,提高运营效率 [12] - 加强与国家DSO、IDN和大集团实践的合作,扩大市场份额 [9] - 推出Detect AI和AI驱动的X光分析工具,推动人工智能在牙科领域的应用 [11] - 预计2023年运营收入将实现高个位数到低两位数的增长,排除PPE产品和COVID-19检测试剂盒的影响 [13] 管理层对经营环境和未来前景的评论 - 尽管面临宏观经济担忧和外汇逆风,公司仍实现了强劲的第四季度和全年业绩 [8] - 预计2023年PPE产品和COVID-19检测试剂盒销售额将大幅下降,但对核心业务的盈利势头充满信心 [13] - 预计2023年医疗和牙科业务将恢复到更正常的增长水平 [27] - 对2023年业绩展望持乐观态度,预计核心业务将实现强劲增长 [46] - 预计2023年第一季度牙科就诊量将恢复到接近2019年的水平 [53] - 预计2023年医疗就诊量将保持稳定,牙科就诊量将略有下降 [53] 其他重要信息 - 2022年第四季度包含一个额外的销售周,下一次出现这种情况将在2028年 [29] - 2023年将修改非GAAP报告,排除收购无形资产的摊销费用 [34] - 2022年第四季度回购了约360万股股票,总价值2.85亿美元 [37] - 2022年全年回购了约610万股股票,总价值4.85亿美元 [37] - 2023年2月8日,董事会批准了额外的4亿美元股票回购授权 [37] - 2022年第四季度记录了1.21亿美元的重组和整合费用,主要与总部大楼腾空和无形资产减值有关 [39] - 预计2023年将继续记录重组和整合费用,但具体金额尚未确定 [40] - 2023年预计有效税率为23%左右 [45] 问答环节所有提问和回答 问题: PPE和COVID检测试剂盒的利润率影响 - 2023年PPE和COVID检测试剂盒销售额下降对利润率的负面影响主要来自毛利润美元的减少,而非毛利率本身 [47][48] 问题: 2023年有机增长预期 - 2023年有机增长预期为3% - 6%,排除PPE和COVID检测试剂盒的影响 [49][50] - 预计牙科业务增长略低于整体,医疗业务增长高于整体 [51] 问题: 2023年牙科和医疗就诊量预期 - 预计2023年第一季度牙科就诊量将恢复到接近2019年的水平 [52][53][54][55][56][57][58][59][60] - 预计2023年医疗就诊量将保持稳定,牙科就诊量将略有下降 [53][54][55][56][57][58][59][60] 问题: 2023年核心业务利润率预期 - 预计2023年核心业务将实现高个位数到低两位数的运营收入增长,并带来利润率扩张 [64][65][66][69] - 利润率扩张主要由产品组合改善驱动,而非运营费用减少 [70] 问题: 2023年重组费用的影响 - 预计2023年核心业务将继续保持高个位数到低两位数的增长,重组费用不会显著影响这一趋势 [73][74] 问题: 牙科专业产品市场表现 - 牙科专业产品,特别是植入物和骨再生产品,在核心市场表现良好,预计将继续增长 [75][76] 问题: 口腔内扫描仪市场前景 - 口腔内扫描仪市场正在向更低价格的产品转变,但高端产品仍有需求 [78][79] - 预计未来几年口腔内扫描仪的普及率将继续提高 [79] 问题: 3D打印对业务的影响 - 3D打印正在取代部分椅旁铣床的需求,但整体市场仍处于早期阶段 [83][84][85][86] - 公司正在积极推广3D打印技术,预计未来几年将取得进展 [84][85][86] 问题: 2023年业绩展望是否包含Biotech Dental - 2023年业绩展望不包含Biotech Dental,预计其对2023年业绩略有稀释 [87][88]

Q4 FY2022 Earnings Conference Call Financial Results & Outlook ZHENRY SCHEIN® In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not g ...

Henry Schein, Inc. (NASDAQ:HSIC) Q3 2022 Earnings Conference Call November 1, 2022 10:00 AM ET Company Participants Graham Stanley - VP of IR & Strategic Financial Project Officer Stanley Bergman - Executive Chairman & CEO Ron South - SVP & CFO Conference Call Participants Jeff Johnson - Baird Elizabeth Anderson - Evercore ISI Brandon Vazquez - William Blair A.J. Rice - Credit Suisse Jon Block - Stifel Erin Wright - Morgan Stanley Jason Bednar - Piper Sandler Operator Good morning, ladies and gentlemen, and ...

ZHENRY SCHEIN® Q3 2022 NASDAQ: HSIC Safe Harbor Provision Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking ...

Henry Schein, Inc. (NASDAQ:HSIC) Q2 2022 Earnings Conference Call August 2, 2022 10:00 AM ET Company Participants Graham Stanley - Vice President of Investor Relations & Strategic Financial Project Officer Stanley Bergman - Executive Chairman & Chief Executive Officer Ron South - Senior Vice President & Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Andrew Brackmann - William Blair Jon Block - Stifel Jeff Johnson - Baird A.J. Rice - Credit Suisse Operator Good morning, lad ...

ZHENRY SCHEIN® Q2 2022 NASDAQ: HSIC Safe Harbor Provision Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking ...

Henry Schein, Inc. (NASDAQ:HSIC) Q1 2022 Earnings Conference Call May 3, 2022 10:00 AM ET Company Participants Stanley Bergman – Chairman and Chief Executive Officer Ronald South – Senior Vice President and Chief Financial Officer Graham Stanley – Vice President Investor Relations and Strategic Finance Project Officer Conference Call Participants Jeff Johnson – Baird Jason Bednar – Piper Sandler Justin Lin – William Blair Elizabeth Anderson – Evercore ISI Nathan Rich – Goldman Sachs Justin Wang – Credit Sui ...

ZHENRY SCHEIN® Q1 2022 NASDAQ: HSIC Safe Harbor Provision Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking ...

ZHENRY SCHEIN® Q4 2021 NASDAQ: HSIC Safe Harbor Provision Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking ...

Henry Schein, Inc. (NASDAQ:HSIC) Q4 2021 Earnings Conference Call February 15, 2022 10:00 AM ET Company Participants Graham Stanley - Vice President, Investor Relations and Strategic Financial Project Officer Stanley Bergman - Chairman and Chief Executive Officer Steven Paladino - Executive Vice President and Chief Financial Officer Ron South - Vice President, Corporate Finance and Chief Accounting Officer Conference Call Participants Matt Miksic - Credit Suisse Jeff Johnson - Baird Nathan Rich - Goldman Sa ...